Literature DB >> 29674613

Risk factors and disease mechanisms in myositis.

Frederick W Miller1, Janine A Lamb2, Jens Schmidt3, Kanneboyina Nagaraju4.   

Abstract

Autoimmune diseases develop as a result of chronic inflammation owing to interactions between genes and the environment. However, the mechanisms by which autoimmune diseases evolve remain poorly understood. Newly discovered risk factors and pathogenic processes in the various idiopathic inflammatory myopathy (IIM) phenotypes (known collectively as myositis) have illuminated innovative approaches for understanding these diseases. The HLA 8.1 ancestral haplotype is a key risk factor for major IIM phenotypes in some populations, and several genetic variants associated with other autoimmune diseases have been identified as IIM risk factors. Environmental risk factors are less well studied than genetic factors but might include viruses, bacteria, ultraviolet radiation, smoking, occupational and perinatal exposures and a growing list of drugs (including biologic agents) and dietary supplements. Disease mechanisms vary by phenotype, with evidence of shared innate and adaptive immune and metabolic pathways in some phenotypes but unique pathways in others. The heterogeneity and rarity of the IIMs make advancements in diagnosis and treatment cumbersome. Novel approaches, better-defined phenotypes, and international, multidisciplinary consensus have contributed to progress, and it is hoped that these methods will eventually enable therapeutic intervention before the onset or major progression of disease. In the future, preemptive strategies for IIM management might be possible.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29674613      PMCID: PMC6745704          DOI: 10.1038/nrrheum.2018.48

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  189 in total

1.  [A case of myositis associated with clonal expansion of γδ T cells in peripheral blood and bone marrow].

Authors:  Taiji Yamashita; Hirohumi Ochi; Naoaki Ishizu; Yasumasa Ohyagi; Yasuo Mori; Sou Arahata; Koichi Ohshima; Jun-Ichi Kira
Journal:  Rinsho Shinkeigaku       Date:  2012

Review 2.  Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study.

Authors:  Lucile Musset; Yves Allenbach; Olivier Benveniste; Olivier Boyer; Xavier Bossuyt; Chelsea Bentow; Joe Phillips; Andrew Mammen; Philip Van Damme; René Westhovens; Anna Ghirardello; Andrea Doria; May Y Choi; Marvin J Fritzler; Heinrike Schmeling; Yoshinao Muro; Ignacio García-De La Torre; Miguel A Ortiz-Villalvazo; Nicola Bizzaro; Maria Infantino; Tiziana Imbastaro; Qinglin Peng; Guochun Wang; Jiří Vencovský; Martin Klein; Olga Krystufkova; Franco Franceschini; Micaela Fredi; Sophie Hue; Thibaut Belmondo; Katalin Danko; Michael Mahler
Journal:  Autoimmun Rev       Date:  2016-08-01       Impact factor: 9.754

3.  Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan.

Authors:  Jeffrey A Allen; Alicia Peterson; Robert Sufit; Monique E Hinchcliff; J Matthew Mahoney; Tammara A Wood; Frederick W Miller; Michael L Whitfield; John Varga
Journal:  Arthritis Rheum       Date:  2011-11

Review 4.  Insights from populations at risk for the future development of classified rheumatoid arthritis.

Authors:  V Michael Holers
Journal:  Rheum Dis Clin North Am       Date:  2014-09-06       Impact factor: 2.670

5.  Skeletal muscle pathology in 2 siblings infected with Toxoplasma gondii.

Authors:  E E Calore; R Minkovski; Z Khoury; A C Seguro; N M Perez Calore; M J Cavaliere
Journal:  J Rheumatol       Date:  2000-06       Impact factor: 4.666

6.  Expression of Toll-like receptor 3 and Toll-like receptor 7 in muscle is characteristic of inflammatory myopathy and is differentially regulated by Th1 and Th17 cytokines.

Authors:  A Tournadre; V Lenief; P Miossec
Journal:  Arthritis Rheum       Date:  2010-07

7.  Chaperone-mediated autophagy components are upregulated in sporadic inclusion-body myositis muscle fibres.

Authors:  M Cacciottolo; A Nogalska; C D'Agostino; W K Engel; V Askanas
Journal:  Neuropathol Appl Neurobiol       Date:  2013-12       Impact factor: 8.090

8.  Myofiber stress-response in myositis: parallel investigations on patients and experimental animal models of muscle regeneration and systemic inflammation.

Authors:  Maurizio Vitadello; Andrea Doria; Elena Tarricone; Anna Ghirardello; Luisa Gorza
Journal:  Arthritis Res Ther       Date:  2010-03-24       Impact factor: 5.156

9.  Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle.

Authors:  Gaetano Vattemi; W King Engel; Janis McFerrin; Valerie Askanas
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

10.  Enhanced expression of MHC class I molecules on cultured human thyroid follicular cells infected with reovirus through induction of type 1 interferons.

Authors:  M S Atta; W L Irving; R J Powell; I Todd
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

View more
  41 in total

1.  Slicing and dicing myositis for cures and prevention.

Authors:  Frederick W Miller
Journal:  Nat Rev Rheumatol       Date:  2021-05       Impact factor: 20.543

2.  High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.

Authors:  Travis B Kinder; Patricia K Dranchak; James Inglese
Journal:  ACS Chem Biol       Date:  2020-06-10       Impact factor: 5.100

Review 3.  Idiopathic inflammatory myopathies.

Authors:  Ingrid E Lundberg; Manabu Fujimoto; Jiri Vencovsky; Rohit Aggarwal; Marie Holmqvist; Lisa Christopher-Stine; Andrew L Mammen; Frederick W Miller
Journal:  Nat Rev Dis Primers       Date:  2021-12-02       Impact factor: 52.329

4.  The Role of Glycosylation in Inflammatory Diseases.

Authors:  Inês Alves; Manuel M Vicente; Ana M Dias; Joana Gaifem; Cláudia Rodrigues; Ana Campar; Salomé S Pinho
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 3.650

5.  Phage display of environmental protein toxins and virulence factors reveals the prevalence, persistence, and genetics of antibody responses.

Authors:  Julia W Angkeow; Daniel R Monaco; Athena Chen; Thiagarajan Venkataraman; Sahana Jayaraman; Cristian Valencia; Brandon M Sie; Thomas Liechti; Payam N Farhadi; Gabriela Funez-dePagnier; Cheryl A Sherman-Baust; May Q Wong; Ingo Ruczinski; Patrizio Caturegli; Cynthia L Sears; Patricia J Simner; June L Round; Priya Duggal; Uri Laserson; Theodore S Steiner; Ranjan Sen; Thomas E Lloyd; Mario Roederer; Andrew L Mammen; Randy S Longman; Lisa G Rider; H Benjamin Larman
Journal:  Immunity       Date:  2022-05-31       Impact factor: 43.474

6.  Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis.

Authors:  Takayuki Kishi; Jonathan Chipman; Melvina Evereklian; Khanh Nghiem; Maryalice Stetler-Stevenson; Margaret E Rick; Michael Centola; Frederick W Miller; Lisa G Rider
Journal:  J Rheumatol       Date:  2019-08-01       Impact factor: 4.666

7.  Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America.

Authors:  Gulnara Mamyrova; Takayuki Kishi; Min Shi; Ira N Targoff; Adam M Huber; Rodolfo V Curiel; Frederick W Miller; Lisa G Rider
Journal:  Rheumatology (Oxford)       Date:  2021-04-06       Impact factor: 7.580

8.  Geographical Latitude Remains as an Important Factor for the Prevalence of Some Myositis Autoantibodies: A Systematic Review.

Authors:  Andrea Aguilar-Vazquez; Efrain Chavarria-Avila; Oscar Pizano-Martinez; Alejandra Ramos-Hernandez; Lilia Andrade-Ortega; Edy-David Rubio-Arellano; Monica Vazquez-Del Mercado
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

9.  The effect of a 24-week training focused on activities of daily living, muscle strengthening, and stability in idiopathic inflammatory myopathies: a monocentric controlled study with follow-up.

Authors:  Maja Špiritović; Barbora Heřmánková; Sabína Oreská; Hana Štorkánová; Olga Růžičková; Lucia Vernerová; Martin Klein; Kateřina Kubínová; Hana Šmucrová; Adéla Rathouská; Petr Česák; Martin Komarc; Václav Bunc; Karel Pavelka; Ladislav Šenolt; Heřman Mann; Jiří Vencovský; Michal Tomčík
Journal:  Arthritis Res Ther       Date:  2021-06-21       Impact factor: 5.156

Review 10.  Updates on interferon in juvenile dermatomyositis: pathogenesis and therapy.

Authors:  Hanna Kim
Journal:  Curr Opin Rheumatol       Date:  2021-09-01       Impact factor: 4.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.